{"id":"placebo-oral-baclofen","safety":{"commonSideEffects":[{"rate":"10-15%","effect":"Drowsiness"},{"rate":"5-15%","effect":"Dizziness"},{"rate":"5-10%","effect":"Weakness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-8%","effect":"Headache"},{"rate":"3-5%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Baclofen acts as a selective agonist at GABA-B receptors, which are inhibitory G-protein coupled receptors found throughout the spinal cord and brain. By activating these receptors, baclofen increases inhibitory neurotransmission, leading to reduced excitability of motor neurons and decreased muscle tone. This mechanism makes it effective for treating spasticity associated with spinal cord injury, multiple sclerosis, and other neurological conditions.","oneSentence":"Baclofen is a GABA-B receptor agonist that enhances inhibitory neurotransmission in the central nervous system to reduce muscle spasticity and hyperreflexia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:19.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle spasticity associated with spinal cord injury"},{"name":"Spasticity in multiple sclerosis"},{"name":"Spasticity from other neurological conditions"}]},"trialDetails":[{"nctId":"NCT05935553","phase":"PHASE2, PHASE3","title":"Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01-15","conditions":"Benzodiazepine Dependence","enrollment":93},{"nctId":"NCT01604330","phase":"PHASE2, PHASE3","title":"Baclofen for the Treatment of Alcohol Drinkers","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-05-29","conditions":"Alcoholism","enrollment":323},{"nctId":"NCT05092841","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A","status":"COMPLETED","sponsor":"Tasly GeneNet Pharmaceuticals Co., Ltd","startDate":"2021-09-28","conditions":"Charcot-Marie-Tooth Type 1A","enrollment":176},{"nctId":"NCT05161351","phase":"PHASE4","title":"Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2021-07-23","conditions":"Addiction Opiate","enrollment":16},{"nctId":"NCT06274021","phase":"EARLY_PHASE1","title":"Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury","status":"RECRUITING","sponsor":"University of Mississippi Medical Center","startDate":"2024-03-01","conditions":"Spinal Cord Injuries, Spinal Cord Injury, Spinal Cord Injury Cervical","enrollment":16},{"nctId":"NCT05877807","phase":"","title":"Effect of Baclofen to Prevent Post-Traumatic Stress Disorder","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2023-09-03","conditions":"Alcoholism, Post Traumatic Stress Disorder","enrollment":94},{"nctId":"NCT04271332","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Clinical Research Associates, LLC","startDate":"2022-09-01","conditions":"16P11.2 Deletion Syndrome","enrollment":60},{"nctId":"NCT04762758","phase":"PHASE3","title":"Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pharnext S.C.A.","startDate":"2021-03-30","conditions":"Charcot-Marie-Tooth Disease","enrollment":350},{"nctId":"NCT03682978","phase":"PHASE2","title":"Arbaclofen in Children and Adolescents With ASD","status":"COMPLETED","sponsor":"Celso Arango, MD, PhD","startDate":"2019-09-19","conditions":"Autism Spectrum Disorder","enrollment":124},{"nctId":"NCT03594552","phase":"NA","title":"Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)","status":"COMPLETED","sponsor":"King's College London","startDate":"2018-02-01","conditions":"Autism Spectrum Disorder","enrollment":87},{"nctId":"NCT01743651","phase":"PHASE3","title":"Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis","status":"COMPLETED","sponsor":"RVL Pharmaceuticals, Inc.","startDate":"2012-11","conditions":"Spasticity, Multiple Sclerosis","enrollment":353},{"nctId":"NCT03293017","phase":"PHASE4","title":"Baclofen in Managing Acute Alcohol Withdrawal","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2016-02-01","conditions":"Alcohol Use Disorder, Alcohol Withdrawal","enrollment":90},{"nctId":"NCT02462317","phase":"PHASE4","title":"Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2015-04","conditions":"Muscle Spasticity","enrollment":184},{"nctId":"NCT03034408","phase":"PHASE2","title":"Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects","status":"COMPLETED","sponsor":"Prof. Daniele Zullino","startDate":"2016-07-01","conditions":"Alcohol Use Disorder","enrollment":37},{"nctId":"NCT02723383","phase":"PHASE3","title":"Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2016-06-27","conditions":"Alcoholism","enrollment":314},{"nctId":"NCT00752934","phase":"PHASE4","title":"Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?","status":"TERMINATED","sponsor":"Shaare Zedek Medical Center","startDate":"2010-10","conditions":"Cerebral Palsy","enrollment":20},{"nctId":"NCT02052440","phase":"PHASE3","title":"Preventing Alcohol Withdrawal Syndrome With Oral Baclofen","status":"TERMINATED","sponsor":"Denver Health and Hospital Authority","startDate":"2014-03-15","conditions":"Alcohol Withdrawal Syndrome","enrollment":102},{"nctId":"NCT00640003","phase":"EARLY_PHASE1","title":"Baclofen Treatment of Ataxia Telangiectasia","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-04","conditions":"Ataxia Telangiectasia","enrollment":10},{"nctId":"NCT01937364","phase":"PHASE2","title":"Preventing Alcohol Withdrawal With Oral Baclofen","status":"TERMINATED","sponsor":"Essentia Health","startDate":"2013-11","conditions":"Alcoholism, Alcohol Withdrawal","enrollment":17},{"nctId":"NCT03113396","phase":"PHASE4","title":"Baclofen for Rumination","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2012-02-01","conditions":"Rumination, Supra-gastric Belching","enrollment":20},{"nctId":"NCT02529514","phase":"PHASE4","title":"Usage of Baclofen for Sleep Improvement After Cardiac Surgery","status":"SUSPENDED","sponsor":"University of Liege","startDate":"2015-07","conditions":"Sleep","enrollment":30},{"nctId":"NCT02361424","phase":"PHASE2","title":"Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)","status":"COMPLETED","sponsor":"Pharnext S.C.A.","startDate":"2013-02","conditions":"Alzheimer Disease","enrollment":47},{"nctId":"NCT00257894","phase":"PHASE2","title":"Baclofen Effects on Smoking Urge and Withdrawal","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2005-12","conditions":"Nicotine Use Disorder, Nicotine Dependence, Smoking","enrollment":41},{"nctId":"NCT01172509","phase":"PHASE1","title":"TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers","status":"TERMINATED","sponsor":"Gonzalez-Heydrich, Joseph, M.D.","startDate":"2010-10","conditions":"Autism","enrollment":6},{"nctId":"NCT01266655","phase":"PHASE2, PHASE3","title":"Baclofen for the Treatment of Alcohol Dependence","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-02","conditions":"Alcohol Dependence","enrollment":56},{"nctId":"NCT00280280","phase":"PHASE1","title":"Botox vs. Baclofen for Upper Limb Spasticity","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2006-02","conditions":"Spasticity","enrollment":8},{"nctId":"NCT00597701","phase":"NA","title":"Treating Alcohol Withdrawal With Oral Baclofen","status":"COMPLETED","sponsor":"Essentia Health","startDate":"2003-04","conditions":"Alcohol Withdrawal Delirium","enrollment":79},{"nctId":"NCT00525252","phase":"PHASE1, PHASE2","title":"Efficacy of Baclofen in the Treatment of Alcohol Addiction","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2003-02","conditions":"Liver Cirrhosis, Alcoholic","enrollment":86},{"nctId":"NCT00414856","phase":"PHASE1","title":"Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Gastroesophageal Reflux Disease","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo + oral baclofen","genericName":"placebo + oral baclofen","companyName":"Shaare Zedek Medical Center","companyId":"shaare-zedek-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baclofen is a GABA-B receptor agonist that enhances inhibitory neurotransmission in the central nervous system to reduce muscle spasticity and hyperreflexia. Used for Muscle spasticity associated with spinal cord injury, Spasticity in multiple sclerosis, Spasticity from other neurological conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}